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esponsibility of InstAbstract Despite the application of aggressive surgery, radiotherapy and chemotherapy in clinics, brain
tumors are still a difﬁcult health challenge due to their fast development and poor prognosis. Brain tumor-
targeted drug delivery systems, which increase drug accumulation in the tumor region and reduce toxicity
in normal brain and peripheral tissue, are a promising new approach to brain tumor treatments. Since brain
tumors exhibit many distinctive characteristics relative to tumors growing in peripheral tissues, potential
targets based on continuously changing vascular characteristics and the microenvironment can be utilized
to facilitate effective brain tumor-targeted drug delivery. In this review, we brieﬂy describe the
physiological characteristics of brain tumors, including blood–brain/brain tumor barriers, the tumor
microenvironment, and tumor stem cells. We also review targeted delivery strategies and introduce a
systematic targeted drug delivery strategy to overcome the challenges.
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X. Wei et al.1941. Introduction
According to the GLOBOCAN 2008, the worldwide cancer inci-
dence of malignant brain tumors is 3.5 per 100,000 people and about
650 people are diagnosed with malignant brain tumors every day1.
Brain tumors severely threaten human health due to their fast
development and poor prognosis. Glioma, the most frequent primary
brain cancer, accounts for 29% of all primary brain and CNS tumors
and 80% of malignant brain tumors2. The median overall survival of
patients with glioblastoma (GBM) is only 14.6 months after current
multimodal treatment–aggressive surgical resection followed by
concurrent or sequential radiation and temozolomide chemothera-
pies3. One reason why poor prognosis and rapid recurrence are
associated with this standard therapy is that the inﬁltrate growth of
gliomas makes it difﬁcult for the surgeon to completely remove
pathologic or cancer-inﬁltrated tissues without affecting normal brain
functions4. Furthermore, the failure is also ascribed to the side effects
of radiotherapy and poor outcome of usual chemotherapy. For many
years, researchers have endeavored to deliver therapeutic agents to the
tumor region effectively and reduce unnecessary drug accumulation
in normal brain and peripheral tissues. For brain tumors, active
targeted drug delivery systems have attracted extensive attention in
recent decades. Since brain tumors possess many distinctive char-
acteristics from peripheral tumors due to their complicated oncogen-
esis, many factors must be taken into consideration for effective brain
tumor-targeted drug delivery, such as the barriers included in the
whole process, the tumor microenvironment, and tumor cells. Now
various targets have been exploited to achieve the targeting therapy
using nanocarriers. Herein we provide a brief review of several
possible targeting delivery strategies for brain tumors.2. Barriers to targeted drug delivery strategies
The oncogenesis of gliomas is complicated, with various barriers
preventing drug from reaching the tumor sites. There are three
main barriers for brain tumor treatment: the blood–brain barrier
(BBB), the blood–brain tumor barrier (BBTB), and a relatively
weak EPR effect. Speciﬁc brain tumor development stages require
corresponding barrier targeting treatment strategies.
2.1. BBB targeting strategies and related drug delivery systems
At the early stage of brain tumor development and at the inﬁltration
growth region of the tumor, the blood–brain barrier remains intact.
The blood–brain barrier, which acts as a natural guard to protect the
brain from harmful substances in the blood stream while supplying
the brain with the necessary nutrients for proper function, is the key
challenge for delivering drugs to brain tumor5. The BBB is a
specialized system of capillary endothelial cells which are partially
covered by pericytes and basement membrane, and almost fully
surrounded by the end feet of astrocytes, preventing approximately
98% of the small molecules and nearly 100% of large molecules
including recombinant proteins and genes from being transported into
the brain and reaching the tumor sites6,7. The BBB strictly limits drug
transport into the brain by serving as a physical (tight junctions),
metabolic (enzymes) and immunological barrier8.
To tackle this challenge, many kinds of active targeting strategies
were adopted for developing effective drug delivery systems to the
brain. The active targeting systems are mainly divided into absorptive-
mediated transcytosis (AMT), transporter-mediated transcytosis, and
receptor-mediated endocytosis (RMT)8.2.1.1. Absorptive-mediated transcytosis
Absorptive-mediated transcytosis provides a means for the delivery of
drugs across the BBB by cationic proteins or cell-penetrating peptides
(CPPs). It is triggered by electrostatic interactions between the
positively charged moieties of the proteins and negatively charged
membrane surface regions on the brain endothelial cells9. Typical
cationic bovine serum albumin-conjugated, pegylated nanoparticles
(CBSA-NP) were prepared by Lu et al.10 for brain targeting. They
demonstrated that the permeability of CBSA-NP was about 7.76
times higher than that of BSA-NP, which offered the possibility of
delivering therapeutic agents to CNS. It was reported that plasmid
pORF-hTRAIL (pDNA)-incorporated CBSA-NP (CBSA-NP-
hTRAIL) colocalized with glycoproteins in brain and tumor micro-
vasculature and accumulated in tumor cells at 30 min after i.v.
administration to C6 glioma bearing nude mice, via absorptive-
mediated transcytosis11. Aclarubicin (ACL)-loaded cationic albumin-
conjugated pegylated nanoparticles (CBSA-NP-ACL) could signiﬁ-
cantly prolong the survival of the intracranial glioblastoma-bearing
mice12. Du et al.13 adopted another cationic protein, wheat germ
agglutinin (WGA) conjugated to the surface of liposomes and also
demonstrated enhanced BBB transport.
Furthermore, alternative AMT-type cell-penetrating peptide (CPP)-
based delivery systems show great ability in BBB transport. CPPs have
been used to overcome the lipophilic barrier of cellular membranes and
deliver a large variety of cargoes, including peptide/proteins, DNA/
oligonucleotide, antibodies, imaging agents, toxins, and nanodrug
carriers such as liposomes and micelles14. CPPs are heterogeneous in
size and sequence and are positively charged. Some share common
features such as an amphipathic sequence and the ability to interact
with lipid membranes. The CPPs are always derived from natural
proteins including the transcription-activating factor Tat, penetratin, and
the Syn-B vectors, among which Tat might be the most frequently
used15. Qin et al.16 covalently conjugated cell-penetrating peptide TAT
(AYGRKKRRQRRR) to cholesterol for preparing doxorubicin-loaded
liposomes for glioma therapy. The biodistribution in the brain and heart
demonstrated higher efﬁciency of brain delivery and lower cardiotoxi-
city. The survival time of the glioma-bearing rats treated with
TAT-modiﬁed liposomes was signiﬁcant prolonged16. Moreover,
self-assembled polymeric micelles modiﬁed with transcriptional acti-
vator TAT peptide (TAT-PEG-b-Col) were constructed by Liu et al.17
to successfully deliver antibiotics across the BBB. These studies show
the potential of Tat-modiﬁed nanoparticle transport into the brain for
the diagnosis and treatment of brain diseases18.2.1.2. Transporter mediated transcytosis
Since there are many kinds of transport systems in the cerebral
endothelium that provide the brain with the necessary nutrients and
endogenous substances, transporter mediated transcytosis takes
advantage of these transport systems as a promising brain targeting
strategy. Transporter mediated transcytosis is substrate-selective,
so only drugs that closely mimic the endogenous substrates will be
taken up and transported into the brain6.
Glucose transporters (GLUT), which facilitate the transport of
glucose from the blood to the brain, have a broad prospective use
in brain targeting. Liposomes that incorporated a mannose
derivative were able to cross the BBB via the glucose transporter
GLUT1 in mouse brain19. Qin et al.20 synthesized a new glycosyl
derivative of cholesterol as a material for preparing novel
liposomes to overcome the ineffective delivery of normal drug
formulations to brain by targeting the glucose transporters on the
BBB. Pharmacokinetic and distribution experiments demonstrated
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targeting ability. Another important transport system is the choline
transporter which binds positively charged quaternary ammonium
groups or simple cations21. Fenart et al.22 examined the ability of
60 nm nanoparticles coated with quaternary ammonium ligands to
cross a cell culture model of the blood–brain barrier (BBB) formed
by a coculture of bovine brain capillary endothelial cells and rat
astrocytes. The coated nanoparticles were able to cross an in vitro
model of the BBB (bovine BCEC). Their passage through the
endothelial cell monolayer was three- or four-fold higher than that
of uncoated nanoparticles, without any modiﬁcation of paracellular
permeability, suggesting that the enhancement was mediated by
the BBB choline transporter.2.1.3. Receptor mediated transcytosis
Generally, for absorptive-mediated transcytosis the speciﬁcity of this
BBB targeting strategy is poor since the cationic proteins or CPPs
can bind with any negatively charged cell membrane constituents.
Moreover, the potential toxicity and immunogenicity of cationic
proteins or CPPs limit their use. The transporter-mediated transcytosis
is substrate selective, in that only drugs that closely mimic the
endogenous carrier substrates will be taken up and transported into
the brain. Receptor-mediated transcytosis is considered one of the
most mature strategies for brain targeted drug delivery with the
characteristics of high speciﬁcity, selectivity and afﬁnity, although the
ligand may have an effect on homeostasis and natural ligands may
compete with the drug ligand to reduce targeting efﬁciency. Since
many kinds of receptors are expressed on the capillary endothelium
of the brain, such as transferrin receptor (TfR), the low density
lipoprotein receptor (LDLR), the insulin receptor and nicotinic
acetylcholine receptors, targeting ligands, including endogenous
ligands and ligands based on phage display or structure-guided
design, have been exploited to facilitate receptor-mediated BBB
transport of drug delivery systems.
One of the most widely characterized receptor-mediated trans-
cytosis systems for brain targeting is the transferrin receptor (TfR),
which is highly expressed on endothelial cells of the BBB23.
A transferrin-conjugated drug delivery system for BBB delivery
has been developed. Zhang et al.24 prepared transferrin-modiﬁed
paclitaxel-loaded polyphosphoester hybrid micells (TPM), and
in vitro and in vivo brain-targeting efﬁciencies were evaluated. It
was demonstrated that TPM exhibited stronger anti-glioma activity
and the mean survival time of mice bearing intracranial U87 MG
glioma was signiﬁcantly prolonged. However, Tf is likely not an
ideal brain delivery ligand since the Tf-modiﬁed targeted drug
delivery system would have to compete with the natural ligand25.
As an alternative, a mouse monoclonal antibody (MAb) against the
rat TfR, OX26, has been extensively studied. When OX26 is
coupled with the liposomes, transferrin receptor-mediated targeting
of daunomycin to the rat brain was achieved by using an
immunoliposome-based drug delivery system26.
Another common receptor, the low-density lipoprotein (LDL)
receptor-related protein (LRP), has been reported to mediate transport
of various ligands conjugated to nanocarriers across the BBB.
Aprotinin is a LRP ligand and its BBB transport ability was evaluated
using an in vitro model of the BBB and in situ brain perfusion. Its
transcytosis across bovine brain capillary endothelial cell monolayers
was at least 10-fold greater than that of holo-transferrin27. Angiopep,
derived from aprotinin with the Kunitz domains of human proteins,
exhibited even higher transcytosis capacity and parenchymal accu-
mulation. Sun et al.28 reported angiopep-2 modiﬁed cationicliposomes for the efﬁcient co-delivery of a therapeutic gene with
paclitaxel to the brain. After treatment with liposomes, the median
survival time of brain tumor-bearing mice was signiﬁcantly longer
than that of other groups, making it a promising drug delivery
strategy against glioma.
Nicotinic acetylcholine receptors (nAChRs) are a kind of
ligand-gated ion channel that is widely expressed in the brain
including the brain capillary endothelial cells29. Since they bind
the second loop of the three-ﬁnger snake toxin with high afﬁnity
and selectivity, nAChRs could be exploited to facilitate BBB
crossing and intracranial transport of drug delivery systems.
Kumar et al.30 reported that a 29-amino acid peptide derived from
rabies virus glycoprotein-RVG29 enabled transvascular siRNA
delivery to the brain via nAChRs and provided a safe and
noninvasive approach for the delivery of therapeutic agents across
the BBB. Therefore, nAChR-mediated brain targeting may be a
promising strategy for the intracranial transport of drug delivery
systems. It was previously reported that a 16 amino acid peptide
CDX, which was derived from the loop II region of the snake
neurotoxin candoxin, exhibited high binding afﬁnity to nicotine
acetylcholine receptors. It was shown that this peptide enabled
brain-targeted drug delivery when conjugated to micelles and
signiﬁcantly prolonged the survival time of intracranial
glioblastoma-bearing mice31.2.2. BBTB targeting strategies and related drug delivery systems
The blood–brain tumor barrier (BBTB), similar to blood–brain barrier
(BBB), is located between brain tumor tissues and microvessels
formed by highly specialized endothelial cells (ECs), limiting the
paracellular delivery of most hydrophilic molecules to tumor tissue32.
With the development of brain tumors, tumor cells begin to invade
the surrounding normal brain tissue. Only when the tumor cell
clusters grow to a certain volume will BBB be damaged and BBTB
be formed. The blood–tumor barrier (BTB) of malignant solid tumors
growing in peripheral tissues is typically more permeable than the
BBTB of similar malignant solid tumors growing in the brain33,34.
The physiologic upper limit of pore size in the BTB of malignant
solid tumor-orthotopic RG-2 rat gliomas microvasculature is approxi-
mately 12 nm35.
With the deterioration of brain tumors, angiogenesis and gradual
impairment of BBB, BBTB becomes the main obstacle of drug
delivery nanosystems. At this stage, tumor neovasculature has formed
to support the growth of gliomas. The abnormality of microvessels
enhances the permeability of BBTB, whereas the cranial microenvir-
onment and/or the gliomas speciﬁcity make malignant gliomas less
permeable36,37. Even though the BBB is compromised in malignant
gliomas, the permeability differs from other regions. The inﬁltrating
gliomas, especially around the tumor edge, still utilize the available
brain vasculature and the BBB still limits glioma-targeted transport of
chemotherapeutic agents37. Hence, the receptors present on the BBB/
BBTB provide a chance for gliomas-targeted drug delivery at this
stage. The strategies proposed for BBTB targeting are mainly based
on receptors high expressed on the tumor such as epidermal growth
factor receptors and integrin.
The adhesion receptor integrin, which is overexpressed on tumor
neovasculture and glioblastoma U87 cells, was identiﬁed as a
marker of angiogenic vascular tissue38–40. Particularly, integrin
αvβ3 expression is prominent in malignant glioma but not over-
expressed on normal brain cells. As the ligands for integrin, cyclic
arginine–glycine–aspartic acid (RGD) peptide and its analogs have
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Herein, the integrin–RGD interaction still provides a promising
BBTB-targeted drug delivery strategy. Our group has designed c
(RGDyK)-modiﬁed polyethylene glycol–polyethylenimine (PEG–
PEI) nanoparticles for intracranial glioblastoma-targeted gene deliv-
ery. They exhibited high binding afﬁnity with U87 cells and
facilitated targeted gene delivery against intracranial glioblastoma
in vivo compared to the PEG–PEI gene carrier without RGD
modiﬁcation. It was demonstrated that the therapeutic efﬁcacy of
pORF-hTRAIL of this gene carrier was also enhanced as evidenced
by a signiﬁcantly prolonged survival of intracranial glioblastoma-
bearing nude mice. These results demonstrated the therapeutic
feasibility of this gene delivery system for brain glioblastoma
treatment through mediation of integrin αvβ341. Zhan et al.42
reported a cyclic RGD peptide conjugated PEG–PLA micelle for
the intracranial gliomas targeted chemotherapy, and the median
survival time of mice bearing intracranial U87MG tumor xenografts
was signiﬁcantly prolonged after treated by c(RGDyK)–PEG–PLA–
PTX micelles, suggesting that RGD motif is efﬁcient for targeted
drug delivery to integrin αvβ3-overexpressed glioblastoma.
EGFR, a member of ErbB family of receptors, is a transmem-
brane tyrosine kinase normally expressed in epithelial, mesench-
ymal, and neuronal tissues43,44. Overexpression of the epidermal
growth factor receptor (EGFR) on the BBTB makes it a promising
target for therapy45. EGF and anti-EGFR monoclonal antibody are
the commonly used EGFR ligands mediating glioma-targeted
therapy. Fondell et al.46 adopted epidermal growth factor to target
the EGFR and developed a new two-step targeting strategy to
transport a recently synthesized daunorubicin derivative into
cancer cell nuclei using PEG-stabilized targeting liposomes named
“Nuclisome-particles”. Tsutsui et al.47 constructed a novel drug
delivery system using hybrid bionanocapsules (BNCs) conjugated
with anti-human EGFR antibody and conﬁrmed the speciﬁc
delivery of these BNCs to the brain tumor in the in vivo brain
tumor model. Anti-human EGFR antibody-conjugated immunoli-
posomes also were prepared by Feng et al.48 and successfully
delivered sodium borocaptate into EGFR-overexpressing gliomas
in an animal model of brain tumors.
2.3. EPR effect-based strategies and related drug delivery
systems
As the brain tumor develops, the enhanced permeability and retention
effect (EPR effect) appears even though it is signiﬁcantly weaker in
the cranial microenvironment than in peripheral tumors, which
enables nanosystems with suitable particle size to enter the brain
tumor via endothelial gaps on the microvessels of brain tumors42,49,50.
Some of the nanoscale drug delivery systems have been developed to
make use of the glioma EPR effect for tumor targeting. Huang et al.51
have developed a tumor-targeting nanoparticle system which pos-
sesses passive tumor target ability via the enhanced permeability and
retention effect. This system was able to prolong the survival time of
intracranial U87MG tumor-bearing nude mice.3. Tumor microenvironment
Studies in developmental biology and tumor progression have
demonstrated that the extracellular microenvironment is not simply
a passive structural element in which cells reside, but is an
interactive partner that can be altered by and can alter cellular
processes and responses52.3.1. Lowered extracellular pH
Lowered extracellular pH (pHe) is a common characteristic of
various solid tumors, including brain tumors, which is caused by
the high rate of glycolysis in cancer cells, under both aerobic and
anaerobic conditions53,54. It has been reported that the tumor pHe
is around 5.7–7.2 depending upon tumor histology, tumor volume,
and tumor location, and is lower than normal tissue55,56. Low extra-
cellular pH may be an important factor inducing more aggressive
cancer phenotypes. During recent decades many approaches have
been developed to target various tumors by pHe, including a
shielding/deshielding mechanism or a pH-triggered drug release
mechanism. Huang and coworkers have developed a tumor
targeting nanoparticle system (called dtACCP) that responds to
the lowered tumor pHe and unregulated matrix metalloproteinase 2
(MMP2) expression in the tumor microenvironment. The nano-
particles are modiﬁed with an activatable cell-penetrating peptide
that is quenched by a pH-sensitive masking peptide, linked by a
MMP2 substrate. Once the modiﬁed nanoparticles reach the
glioblastoma microenvironment, the negative charge of the mask-
ing peptide will be eliminated due to the lowered pHe, while the
linker is cleaved by MMP2, exposing CPP to drive the nanopar-
ticle's internalization into the tumor cells51,57. This shielding/
deshielding mechanism makes it feasible to develop a lowered
tumor pHe-triggered drug delivery system, increasing target drug
accumulation at the tumor site and lowering the cytotoxicity to the
normal tissue.3.2. Angiogenesis
With the deterioration of brain tumors, angiogenesis occurs with
new vessels developing from pre-existing ones. Angiogenesis is
essential for glioma tumor growth and metastasis. The angiogen-
esis targeting delivery system is capable of speciﬁcally delivering
anti-angiogenic therapeutics to the tumor neovasculature while
minimizing systematic toxicity. Therefore, receptors highly
expressed during tumor angiogenesis, such as epidermal growth
factor receptors and integrin, provide tumor-targeted drug delivery
strategies as mentioned in the BBTB targeting strategies section.
Currently, antiangiogenic therapy has been restricted to targeting
endothelial cells. It was shown that endothelial cells–pericytes
signaling networks could also contribute to tumor angiogenesis
and metastasis, suggesting that pericytes could be another
promising complementary target for cancer treatment. The acti-
vated pericytes are capable of stabilizing blood vessels, providing
EC survival signals and protecting ECs from VEGF withdrawal,
leading to pericyte-mediated resistance to antiangiogenic thera-
pies58,59. Guan et al.60 developed a pericyte-targeting drug
delivery system, TH10 peptide (TAASGVRSMH)-conjugated
nanoparticles loaded with docetaxel (TH10-DTX-NP) that can
target the NG2 proteoglycan highly expressed in tumor vascular
pericytes. Enhanced antitumor effects were achieved, revealing
the potency and signiﬁcance of targeting tumor vascular pericytes
using nano-DDS in antiangiogenic cancer therapy. It was reported
that doxorubicin-loaded liposomes modiﬁed with peptide ligands
were constructed for the combined therapy of targeting both
tumor pericytes and ECs, displaying enhanced anti-tumor effects
and prolonged survival in human neuroblastoma-bearing mice.
These results clearly demonstrate that this combined targeting
strategy was more effective for destruction of tumor vasculature
than either monotherapy61.
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Vasculogenic mimicry (VM) occurs when highly invasive tumor cells
form vascular channels for transporting plasma and red blood cells to
provide the supply required for tumor growth and metastasis them-
selves. The channels formed by VM, which can be stained by Periodic
Acid-Schiff (PAS), are composed of basement membranes and lined
by tumor cells, and no endothelial cells are found on the inner wall62.
In 1999, Maniotis and colleagues63 found that tissue sections from
aggressive human intraocular (uveal) and metastatic cutaneous mela-
nomas generally lacked evidence of signiﬁcant necrosis and contained
patterned networks of interconnected loops of extracellular matrix. Red
blood cells were detected within these vascular channel networks and
no endothelial cells were identiﬁed by microscopy or an immunohis-
tochemical panel of endothelial cell markers. From then on, research on
vasculogenic mimicry had attracted much more attention and provoked
the further thinking about its molecular regulatory mechanism and its
application in tumor therapy64,65.
With further research, VM has been observed in several malignant
tumor types such as breast cancer, liver cancer, glioma, ovarian
cancer, melanoma, prostate cancer, and others66–69. Vasculogenic
mimicry was previously reported in human glioblastoma tissues and
human glioma cell-line xenografts70. Yue and Chen71 examined 45
astrocytomas (including 15 World Health Organization grade II cases,
15 grade III cases, and 15 grade IV cases) for CD34 endothelial cell
markers and periodic acid-Schiff (PAS) staining, among which
CD34-negative, PAS-positive patterns of VM were observed in
malignant astrocytomas. Hence VM provides new insights for the
therapeutic intervention of tumor-associated vasculature.
Until now little has been known about the molecular mechanisms
involved in VM. It was reported that aggressive VM-positive tumors
exhibited higher expression of the basement membrane extracellular
matrix (ECM) component laminin 5γ2, MMP1, MMP2, MMP9 and
membrane type-1-matrix/metalloproteinase72. Paulis et al.73 consid-
ered the VE-cadherin/EphA2/MMP-2 as one of the key VM signaling
pathways. Besides, the ischemia and hypoxia effects of the local
tumor microenvironment also have an impact on the formation of
VM channels69. Many researchers involved in VM studies have been
trying to treat tumors based on an anti-VM therapy. But almost all
VM targeting therapies have been performed in vitro. Hess et al.74
adopted general inhibitors of protein tyrosine kinases with transient
knockout of EphA2 to abrogate the ability of tumor cells to form
tubular structures. Downregulating VE-cadherin, using antibodies
against human MMPS and the laminin 5γ2 chain are also possible
strategies to inhibit VM75. Francescone and colleagues75 found that
vascular channels of VM in GBM were composed of mural-like
tumor cells that strongly express VEGF receptor 2 (Flk-1). Therefore,
the identiﬁcation of Flk-1 as a key factor regulating VM could offer a
novel therapeutic target for GBM treatment.
It is necessary to combine both classic anti-angiogenesis and anti-
VM in anti-tumor therapies. Tumor cells, which line in the inner
surface of VM channels, are highly malignant and have high
plasticity. They are directly exposed to blood ﬂow and readily allow
tumor cells to migrate and metastasize to other organs. With
traditional anti-angiogenesis therapy, the vasculogenic mimicry could
also nourish the tumor with nutrients and promote metastasis. As a
result, multiple antivascular approaches, including targeting VM and
angiogenesis together, may represent the best possible regimen in the
treatment of tumors. Since VEGF receptors are highly expressed on
angiogenic cells and the VM of GBM, a corresponding ligand-
mediated drug delivery system may be utilized for the tumor targeting
therapy75.4. Tumor cells
Two alternative models have been put forward to explain how
tumors initiate and develop. One is the stochastic model, propos-
ing that tumor cells are heterogeneous, and virtually any of them
can function as a tumor-initiating cell. Another one is the
hierarchical model, encouraged by increasing experimental data,
which hypothesizes that only a small subpopulation of tumor stem
cells can induce tumorigenesis76,77. The normal tumor cells,
accounting for most of the tumor tissue, are incapable of
tumorigenesis and could be killed by common chemotherapeutic
drugs, while cancer stem cells have the ability to self-renew,
spending most of their time in the G0 phase of the cell division
cycle. Cancer stem cells are likely to share many of the properties
of normal stem cells that include a long lifespan, relative
quiescence, resistance to drugs and toxins through the expression
of several ATP-binding cassette (ABC) transporters, an active
DNA-repair capacity, and a resistance to apoptosis77. In recent
years, brain tumor stem cells have been reportedly identiﬁed and
isolated, and the concept of cancer stem cells was extended to
brain tumors78,79. The brain tumor stem cells (BTSC) are capable
for self-renewal, multipotency, and induction of tumorigenesis.
BTSC exhibited remarkable resistance to chemotherapy due to
their relative quiescence, active DNA repair regulatory systems
and high expression of ABC transporters80,81. Thus, for brain
tumor targeted strategies, cancer stem cell targeting is essential.
Recently, several stem cell targeting drug delivery systems have
been constructed. Zhang et al.82 prepared mitochondrial targeting
liposomes showing the strongest efﬁcacy in treating MCF-7 cancer
cells and cancer stem cells in vitro and in treating relapsed tumor
cells in mice. Nevertheless, brain tumor stem cells targeting
nanocarriers are still under research.
CD133, a 120 kDa cell-surface protein, is considered as a marker
of normal human neuronal precursors and could be used for the
enrichment of tumor stem-like cells from brain tumors83,84. Sun and
colleagues85 obtained a speciﬁc mouse CD133 binding peptide
named LS7 (LQNAPRS) by phage-displayed peptide library technol-
ogy, which could be used to target cancer stem cells. Nestin, a
200–240 kDa intermediate ﬁlament protein, is also the most com-
monly used marker for the isolation and study of brain tumor stem
cells. Beck et al.86 identiﬁed an effective Nestin targeted peptide
(AQYLNPS) through the phage display technology, providing a
promising opportunity to design a BTSC-targeted drug delivery
system. BTSC and neuronal stem cells share many characteristics
including these two markers. Up to now, research on BTSC-targeted
drug delivery system is only in its infancy, and speciﬁc targets are
still needed for the BTSC targeted drug delivery systems.5. Conclusions
In actual research practice, several targeting strategies have been
combined to achieve better therapeutic effects. One common dual
targeting drug delivery system was the combination of trans-BBB
targeting and brain tumor cell targeting in two ways. The ﬁrst was
dual-targeting moiety modiﬁcation such as transferrin (Tf) and
wheat germ agglutinin (WGA)87, and p-aminophenyl-α-D-manno-
pyranoside(MAN) and transferrin (Tf)88; the second one is a
single-targeting moiety that targets both BBB and tumor cells,
such as angiopep-2 targeting to LRP overexpressed on both
BBB and glioma cells89,90. Another dual targeting drug delivery
system was combining trans-BBTB targeting with brain tumor cell
X. Wei et al.198targeting. For instance, a single targeting moiety (RGD) was
utilized to target both BBTB and tumor cells42. Anti-angiogenesis
and anti-tumor combination treatments gained much attention
because of the potential for dual inhibition of both tumor
proliferation and tumor invasion. Gao et al. modiﬁed nanoparticles
with interleukin-13 peptide, targeting GBM cells and RGD
targeting the neovasculature to construct a neovasculature and
tumor cell dual targeting delivery, which demonstrated a clear anti-
tumor effect in vitro and in vivo83.
Taken together, although current brain tumor-targeted drug
delivery systems have achieved signiﬁcant advances in various stages
of brain tumors, there are still limitations of the current drug therapy.
As a consequence of these challenges, a series of overall targeting
drug delivery systems called “systematic targeted drug delivery” or
“whole-process targeting” (WPT) were introduced to try to make the
best of every potential target for more effective treatment of brain
tumors48. The “systematic targeted drug delivery” or “whole-processFigure 1 Brain tumor “systemtargeting” is recognized as an effective brain tumor targeted drug
delivery strategy which considers all the possible targets including
barriers, microenvironment and cancer cells. At the early stage of a
brain tumor or around the tumor edge of the inﬁltrating glioma after
BBTB formation, the tumor is nourished by the normal brain
capillary network. Nanocarriers modiﬁed with ligands targeting the
BBB and tumor cells are needed. With the development of the tumor,
tumor neovasculature has formed to support the growth of gliomas.
The BBTB and tumor cells are the main target goals. Along with the
deterioration of the brain tumor, the EPR effect in brain tumor tissues
appears and the nano-drug delivery vesicles enter the tumor tissue via
passive targeting. Furthermore, vasculogenic mimicry, lowered
extracellular pH and tumor stem cells provide possible complemen-
tary targets which should be taken into consideration for better
therapy of the brain tumors (Fig. 1).
Research on “systematic targeted drug delivery” is a promising
approach to the treatment of brain tumors. It will help to ﬁll in theatic targeted drug delivery”.
Brain tumor-targeted drug delivery strategies 199gaps that remain in fully understanding the relationship bet-
ween the physiological and pathological conditions of brain
tumors, providing a basis for various targeted delivery systems.
We believed that systematic targeted drug delivery strategies for
brain tumors that consider characteristics of brain tumor growth
will provide promising ways to treat brain tumor in the future.Acknowledgments
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